Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594332 | 0.85 | ALDH1A1 (0.71) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL7573015 | 0.82 | CCR2 (0.64) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL9931224 | 0.80 | CCR2 (0.70) | BRAFMEN1KMT2AHKDC1CCR2 | |
| SCHEMBL3981382 | 0.79 | METAP2 (0.67) | BRAFMEN1KMT2AHKDC1NPSR1 | |
| SCHEMBL21771105 | 0.79 | BRAF (0.70) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL2247197 | 0.79 | BRAF (1.00) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL26035691 | 0.79 | BRAF (0.70) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL15009888 | 0.78 | ALDH1A1 (0.61) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL7578803 | 0.78 | TP53 (0.73) | BRAFMEN1KMT2AHKDC1TP53 | |
| SCHEMBL7569883 | 0.78 | PKM (0.79) | BRAFMEN1KMT2AHKDC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| EP-2675526-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | Vifor (International) AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | BRAF 2436/4885MEN1 3483/4885KMT2A 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.